New Clues to Preclinical Alzheimer’s Disease

Dr. Rosenberg has received research support from AbbVie, the Alzheimer’s Association, Eli Lilly, and the National Institute on Aging; he has served as a consultant on advisory boards for AbbVie, Avanir, Lundbeck, and Otsuka; and he has received travel support from Avanir and Otsuka. Dr. Lyketsos has received grant support (research or CME) from the Associated Jewish Federation of Baltimore, AstraZeneca, Bristol-Myers Squibb, Eisai, Elan, Eli Lilly, Forest, Functional Neuromodulation, GlaxoSmithKline, the National Football League, the National Institute on Aging, NIMH, Novartis, Ortho-McNeil, Pfizer, and the Weinberg Foundation; he has served as a consultant or adviser for AbbVie, Adlyfe, Astellas, AstraZeneca, Avanir, Bristol-Myers Squibb, Eisai, Elan, Eli Lilly, Forest, Genentech, GlaxoSmithKline, Janssen, Lundbeck, Merck, Merz, the NFL Players Association, the NFL Benefits Office, Novartis, Orion, Otsuka, Pfizer, Supernus, Takeda, Wyeth, and Zinfandel; and he has received honoraria or travel support from Forest, GlaxoSmithKline, Health Monitor, and Pfizer. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.